Overview / Abstract: |
Target Audience This activity has been designed to address the educational needs of primary care clinicians. It may also be of benefit to other healthcare professionals who manage patients with diabetes using glucagon-like peptide-1 (GLP-1) receptor agonists. Program Overview The incidence of diabetes, particularly type 2 diabetes (T2D), is increasing, and with this increase comes an associated rise in diabetes complications and comorbidities such as obesity, cardiovascular disease (CVD), and renal disease. There are several classes of agents to treat hyperglycemia from which clinicians can choose. In recent years, data on GLP-1 receptor agonists have emerged demonstrating beneficial extraglycemic effects, yet the level of benefit varies among different members of the class. Most recent guideline recommendations include preferences for GLP-1 receptor agonists to individualize therapy for patients with diabetes and CVD. Despite these benefits, the uptake of and adherence to GLP-1 receptor agonist therapy is low. Because the majority of T2D management occurs in the primary care setting, primary care providers play a crucial role in optimizing T2D therapy. However, primary care providers are challenged to remain abreast of the latest data on GLP-1 receptor agonists, the clinical distinctions between class members, managing side effects, and strategies for patient education about GLP-1 receptor agonists and how to increase adherence to therapy. Learning Objectives Upon completion of this activity, participants should be better able to: Select treatment for patients who have diabetes based on the extraglycemic effects of GLP-1 receptor agonists |
Expiration |
May 15, 2021 |
Discipline(s) |
Physician CME |
Format |
Online |
Credits / Hours |
0.5 AMA PRA Category 1 Credit(s)™ |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Faculty Vivian Fonseca, MD Javier Morales, MD, FACP, FACE Debbie A. Hinnen, APN, BC-ADM, CDE, FAAN, FAADE |
Sponsors / Supporters / Grant Providers |
Novo Nordisk Inc. |
Keywords / Search Terms |
Relias LLC Relias LLC., FREE CME., Diabetes Free CE CME |